Pfizer Finds Backup For Aricept In Medivation’s Dimebon
This article was originally published in The Pink Sheet Daily
Medivation Alzheimer’s candidate is unique for its disease-modifying potential.
You may also be interested in...
Epigenetics took the spotlight this week, with Genentech being the latest pharma to move into the field in partnership with Constellation Pharmaceuticals. In other deals, Bayer signed Ventana to develop a companion diagnostic, and Pfizer walked away from Medivation and Alzheimer’s drug Dimebon.
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.
After a disastrous failure in Alzheimer's disease last year, Dimebon once again disappoints in a Phase III trial - this time in Huntington disease.